Despite decades of progress, the world is still far from stopping the spread of HIV. We’re committed to doing our part to end the epidemic – especially in areas with the greatest need.
We understand that long-acting HIV PrEP options are critical for people around the world who need alternative choices to reduce their chances of acquiring HIV. We’ve conducted Phase 3 studies of an investigational long-acting PrEP option to help address this need.
We’re committed to achieving broad, sustainable access to long-acting HIV PrEP in high-incidence, resource-limited countries – primarily low- and lower-middle-income countries.
We'll support access to our long-acting PrEP, if approved, in high-incidence, resource-limited countries through a two-part strategy:
Our strategy reflects input from more than 100 global health stakeholders. Through these discussions, four essential priorities have consistently emerged: delivering long-acting PrEP with speed, at sufficient volume to meet demand, at prices that enable widespread availability and in coordination with partners on the ground. These priorities are guiding every step of our strategy.
Our History of Supporting Global Access to Medicines
We’re proud of our two decades of innovation and leadership in global access to medicines. Our partnerships with generic drug manufacturers have helped enable millions of people to benefit from high-quality, low-cost therapies for HIV, viral hepatitis and COVID-19.
8.1 Million
Individuals received COVID-19 treatment to date through voluntary licensing
2.9 Million
HCV treatments manufactured by voluntary licensees to date
20 Million
HIV and HBV treatments made by generic drug manufacturers made available by voluntary licensees in 2023
In total, more than 30 million treatments for HIV, HBV, HCV and COVID-19 have been made available in low- and middle-income countries as a result of partnerships with generic licensees, government and NGOs.